Step Pharma

About Step Pharma

Step Pharma is discovering and developing novel therapeutics that inhibit the enzyme CTP Synthase 1 (CTPS1).

Step Pharma was created on the basis of research on genetic immunodeficiencies led by Prof. Alain Fischer at the Imagine Institute (Paris, France) which established the essential role of CTPS1 in T- and B-cell proliferation.

Latest news

10 June 2022

Step Pharma Presents Encouraging Data on its First-in-Class CTPS1 Inhibitor STP938 at the European Hematology Association Congress

30 May 2022

Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the European Hematology Association Congress 2022

10 May 2022

Step Pharma Strengthens Clinical Development Team Ahead of First in Human Studies

Upcoming events

Step Pharma will be present at the following events

Nothing found.

Share this page

Forum 2
218 avenue Marie Curie
74160 Archamps
France

Developing CTP Synthase 1 inhibitors as novel targeted therapies for cancer and auto-immune diseases